• Supernus Pharmaceuticals agreed to combine with Indivior Pharmaceuticals in an all-stock transaction, creating a CNS-focused drugmaker with scale.
• Combined annual revenue expected at about $2.2 billion; pro forma adjusted EBITDA projected at $888 million.
• Deal targets $125 million in annual cost synergies; closing expected in Q4 2026, subject to shareholder and regulatory clearances.
• Supernus holders to receive 1.5401 Indivior shares per share; Indivior holders to get a one-time $1 billion special cash dividend pre-close.
• Post-close ownership split set at about 56.5% for Indivior shareholders, 43.5% for Supernus shareholders; Rockville, Maryland to serve as global headquarters.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030630PRIMZONEFULLFEED9802295) on August 03, 2026, and is solely responsible for the information contained therein.